https://pasithea.com/pasithea-therapeutics-announces-appointment-of-kartik-krishnan-m-d-ph-d-as-chief-medical-officer/2026-05-04T12:01:00-04:00https://pasithea.com/pasithea-therapeutics-announces-grant-of-rare-pediatric-disease-designation-rpdd-by-fda-to-pas-004-for-treatment-of-neurofibromatosis-type-1-nf1/2026-04-20T12:01:00-04:00https://pasithea.com/pasithea-therapeutics-announces-grant-of-fast-track-designation-by-fda-to-pas-004-for-treatment-of-neurofibromatosis-type-1-nf1-associated-plexiform-neurofibromas-pn-causing-significant-morbidity/2026-04-01T12:01:00-04:00https://pasithea.com/pasithea-therapeutics-to-present-at-the-oppenheimer-36th-annual-healthcare-life-sciences-conference/2026-02-17T13:01:00-05:00https://pasithea.com/pasithea-therapeutics-provides-outlook-on-pas-004-clinical-programs-and-data-release-timelines/2026-01-13T13:01:00-05:00https://pasithea.com/pasithea-therapeutics-announces-closing-of-60-million-public-offering-of-common-stock/2025-12-02T13:00:00-05:00https://pasithea.com/pasithea-therapeutics-announces-pricing-of-60-million-public-offering-of-common-stock/2025-11-28T15:20:00-05:00https://pasithea.com/pasithea-therapeutics-announces-1-million-award-by-als-association-to-study-the-efficacy-safety-and-tolerability-of-pas-004-for-treatment-of-als/2025-11-25T13:00:00-05:00https://pasithea.com/pasithea-therapeutics-announces-completion-of-cohort-7-in-ongoing-phase-1-trial-of-pas-004-in-advanced-cancer-patients-with-positive-safety-pharmacokinetic-pk-and-pharmacodynamic-pd-data/2025-11-24T13:00:00-05:00https://pasithea.com/pasithea-therapeutics-announces-positive-pas-004-tablet-pharmacokinetic-pk-data-in-ongoing-phase-1-1b-trial-in-adult-nf1-patients/2025-11-21T18:35:00-05:00https://pasithea.com/pasithea-therapeutics-announces-positive-phase-1-data-including-partial-response-demonstrating-monotherapy-clinical-activity-and-favorable-safety-profile-for-pas-004-in-advanced-cancer-study/2025-11-20T22:01:00-05:00https://pasithea.com/pasithea-therapeutics-announces-activation-of-clinical-trial-site-at-university-of-alabama-at-birmingham-for-ongoing-phase-1-1b-trial-of-pas-004-in-adult-nf1-patients/2025-11-04T13:03:00-05:00https://pasithea.com/pasithea-therapeutics-announces-activation-of-clinical-trial-sites-in-south-korea-for-phase-1-1b-trial-of-pas-004-in-adult-nf1-patients/2025-09-16T12:03:00-04:00https://pasithea.com/pasithea-therapeutics-announces-enrollment-of-cohort-2-following-positive-safety-review-committee-src-recommendation-for-its-ongoing-phase-1-1b-clinical-trial-of-pas-004-in-adult-nf1-patients/2025-09-08T12:01:00-04:00https://pasithea.com/pasithea-therapeutics-updates-time-of-presentation-at-the-h-c-wainwright-27th-annual-global-investment-conference/2025-08-29T13:39:00-04:00https://pasithea.com/pasithea-therapeutics-to-present-at-the-h-c-wainwright-27th-annual-global-investment-conference/2025-08-28T12:02:00-04:00https://pasithea.com/pasithea-therapeutics-completes-enrollment-and-initial-dosing-of-first-cohort-from-its-phase-1-1b-clinical-trial-of-pas-004-in-adult-nf1-patients/2025-07-31T12:01:00-04:00https://pasithea.com/pasithea-therapeutics-appoints-expert-in-ets2-driven-inflammatory-disease-to-scientific-advisory-board/2025-06-11T12:02:00-04:00https://pasithea.com/pasithea-therapeutics-presents-updated-interim-data-from-ongoing-phase-1-study-of-pas-004-at-the-asco-annual-meeting-2025/2025-06-02T13:02:00-04:00https://pasithea.com/pasithea-therapeutics-announces-preclinical-data-that-shows-pas-004-inhibits-ets2-signaling-a-key-driver-of-inflammation-in-ibd-and-other-large-addressable-market-diseases/2025-05-20T12:01:00-04:00https://pasithea.com/pasithea-therapeutics-announces-initiation-of-phase-1-1b-study-of-pas-004-in-adult-nf1-patients-and-activation-of-first-clinical-trial-site/2025-05-14T12:02:00-04:00https://pasithea.com/pasithea-therapeutics-announces-closing-of-5-million-public-offering/2025-05-07T22:00:00-04:00https://pasithea.com/pasithea-therapeutics-announces-pricing-of-5-million-public-offering/2025-05-06T16:10:00-04:00https://pasithea.com/pasithea-therapeutics-reports-positive-pharmacodynamic-results-demonstrating-robust-target-engagement-from-its-ongoing-phase-1-clinical-trial-of-pas-004/2025-05-06T12:03:00-04:00https://pasithea.com/pasithea-therapeutics-announces-completion-of-enrollment-and-initial-dosing-of-patients-in-cohort-6-from-its-phase-1-trial-of-pas-004-in-advanced-cancer-patients/2025-04-29T12:02:00-04:00https://pasithea.com/pasithea-therapeutics-to-present-updated-data-from-ongoing-phase-1-trial-of-pas-004-in-advanced-cancer-patients-at-the-2025-asco-annual-meeting/2025-04-24T12:02:00-04:00https://pasithea.com/pasithea-therapeutics-announces-positive-safety-review-committee-src-recommendation-from-its-ongoing-phase-1-clinical-trial-of-pas-004-in-advanced-cancer/2025-04-10T12:02:00-04:00https://pasithea.com/pasithea-therapeutics-to-present-at-the-2025-cagla-neauxcancer-conference/2025-03-24T11:59:00-04:00https://pasithea.com/pasithea-therapeutics-announces-positive-safety-review-committee-src-recommendation-from-its-ongoing-phase-1-clinical-trial-of-pas-004-in-advanced-cancer-2/2025-02-05T12:59:00-05:00https://pasithea.com/pasithea-therapeutics-announces-opening-of-european-clinical-trial-sites-and-completes-initial-dosing-of-cohort-4/2025-01-14T14:02:00-05:00https://pasithea.com/pasithea-therapeutics-announces-positive-safety-review-committee-src-recommendation-from-its-ongoing-phase-1-clinical-trial-of-pas-004-in-advanced-cancer-3/2024-11-20T13:02:00-05:00https://pasithea.com/pasithea-therapeutics-announces-5-million-private-placement-priced-at-the-market-under-nasdaq-rules/2024-09-26T23:44:00-04:00https://pasithea.com/pasithea-therapeutics-announces-positive-initial-safety-tolerability-pharmacokinetic-pk-and-preliminary-efficacy-data-from-its-phase-1-clinical-trial-of-pas-004-in-advanced-cancer/2024-09-26T12:02:00-04:00https://pasithea.com/pasithea-therapeutics-announces-successful-completion-of-pas-004-chronic-toxicity-studies/2024-09-09T13:01:00-04:00https://pasithea.com/pasithea-therapeutics-announces-appointment-of-dr-rebecca-brown-to-its-scientific-advisory-board/2024-09-03T13:02:00-04:00https://pasithea.com/pasithea-therapeutics-to-present-at-the-h-c-wainwright-26th-annual-global-investment-conference/2024-08-28T14:11:00-04:00https://pasithea.com/pasithea-therapeutics-announces-completion-of-enrollment-and-initial-dosing-of-cohort-2-following-positive-safety-review-committee-src-recommendation-for-pas-004-in-ongoing-phase-1-clinical-trial/2024-06-13T11:59:00-04:00https://pasithea.com/pasithea-therapeutics-to-present-new-preclinical-data-showing-pas-004-strongly-inhibits-nras-cancer-cell-lines-and-demonstrates-superior-activity-in-xenograft-studies-at-2024-asco-annual-meeting/2024-05-28T11:59:00-04:00https://pasithea.com/pasithea-therapeutics-announces-the-first-cohort-has-completed-the-initial-dosing-in-its-phase-1-trial-evaluating-pas-004-in-ras-nf1-and-raf-mutated-cancers/2024-04-24T12:59:00-04:00https://pasithea.com/pasithea-therapeutics-announces-opening-of-enrollment-in-the-u-s-for-its-phase-1-trial-of-pas-004/2024-02-13T13:59:00-05:00https://pasithea.com/pasithea-therapeutics-announces-invention-of-crystalline-form-of-pas-004-establishes-strengthened-intellectual-property-ip-position/2024-01-08T13:59:00-05:00https://pasithea.com/pasithea-therapeutics-announces-fda-acceptance-of-ind-application-to-evaluate-pas-004-in-advanced-cancer-patients/2024-01-02T14:35:00-05:00https://pasithea.com/pasithea-therapeutics-announces-adjournment-of-reconvened-meeting-of-stockholders-to-december-29-2023/2023-12-28T23:00:00-05:00https://pasithea.com/pasithea-therapeutics-announces-results-from-2023-annual-meeting/2023-12-19T23:19:00-05:00https://pasithea.com/pasithea-therapeutics-announces-positive-in-vivo-preclinical-efficacy-data-for-pas-004-from-nras-mutation-cancer-xenograft-models/2023-12-11T14:01:00-05:00https://pasithea.com/pasithea-therapeutics-announces-adjournment-of-2023-annual-meeting-of-stockholders/2023-11-29T22:27:00-05:00https://pasithea.com/pasithea-therapeutics-announces-outcome-of-pre-ind-meeting-with-fda-for-pas-004-clinical-development/2023-11-29T13:59:00-05:00https://pasithea.com/pasithea-therapeutics-selects-pas-003-lead-development-candidate-a-humanized-monoclonal-antibody-that-targets-51-integrin-for-the-treatment-of-both-sporadic-and-familial-als/2023-11-09T13:59:00-05:00https://pasithea.com/pasithea-therapeutics-corp-announces-final-results-of-tender-offer/2023-09-14T13:30:00-04:00https://pasithea.com/pasithea-therapeutics-to-participate-in-h-c-wainwright-25th-annual-global-investment-conference/2023-09-07T21:14:00-04:00https://pasithea.com/pasithea-therapeutics-publishes-study-in-proceedings-of-the-national-academy-of-sciences-pnas-that-shows-an-increase-in-5-integrin-expression-in-als-human-and-mouse-brain-tissue-and-further-d/2023-08-01T12:59:00-04:00https://pasithea.com/pasithea-therapeutics-announces-intention-to-commence-a-4-0-million-tender-offer-for-its-common-stock-at-price-of-0-70-per-share-in-cash/2023-07-20T13:43:00-04:00https://pasithea.com/pasithea-therapeutics-special-committee-rejects-unsolicited-bid-from-lucy-scientific-discovery-inc/2023-07-20T13:40:00-04:00https://pasithea.com/pasithea-therapeutics-confirms-previous-creation-of-independent-special-committee-of-its-board-of-directors/2023-06-30T14:28:00-04:00https://pasithea.com/pasithea-therapeutics-announces-completion-of-gmp-manufacturing-for-pas-004/2023-06-29T13:29:00-04:00https://pasithea.com/pasithea-therapeutics-confirms-receipt-of-unsolicited-proposal-from-lucy-scientific-discovery-inc/2023-06-06T21:30:00-04:00https://pasithea.com/pasithea-therapeutics-abstract-accepted-for-poster-presentation-at-2023-neurofibromatosis-conference/2023-06-01T12:57:00-04:00https://pasithea.com/pasithea-therapeutics-to-participate-in-ef-hutton-inaugural-global-conference/2023-05-03T13:26:00-04:00https://pasithea.com/pasithea-therapeutics-chairman-prof-lawrence-steinman-to-deliver-keynote-address-at-the-american-association-for-advancement-of-science-aaas-annual-meeting/2023-03-02T14:00:00-05:00https://pasithea.com/pasithea-therapeutics-chairman-prof-lawrence-steinman-to-deliver-dr-kenneth-p-johnson-lecture-at-americas-committee-for-treatment-and-research-in-multiple-sclerosis-actrims/2023-02-23T14:00:00-05:00https://pasithea.com/pasithea-therapeutics-chairman-prof-lawrence-steinman-to-receive-pioneer-in-medicine-award/2023-02-16T13:30:00-05:00https://pasithea.com/pasithea-therapeutics-signs-cmc-development-and-manufacturing-agreement-for-the-production-of-pas-004/2023-01-18T14:00:00-05:00https://pasithea.com/majority-of-stockholders-support-pasithea-directors-at-special-meeting/2022-12-14T23:17:00-05:00https://pasithea.com/pasithea-therapeutics-announces-comprehensive-settlement-agreement-with-the-camac-group/2022-12-12T13:00:00-05:00https://pasithea.com/pasithea-therapeutics-to-present-at-annual-meeting-of-the-antibody-society-conference/2022-12-06T14:00:00-05:00https://pasithea.com/pasithea-therapeutics-postpones-special-meeting-until-december-9-2022-at-900-am-eastern-time/2022-11-29T01:05:00-05:00https://pasithea.com/pasithea-therapeutics-to-present-tolerizing-vaccine-program-results-at-immunotherapy-2022-international-course-and-symposium/2022-10-17T13:00:00-04:00https://pasithea.com/pasithea-therapeutics-appoints-life-sciences-and-health-care-executive-alfred-j-novak-to-its-board-of-directors/2022-09-20T13:00:00-04:00https://pasithea.com/pasithea-therapeutics-further-strengthens-its-scientific-advisory-board-with-the-appointment-of-dr-merit-cudkowicz/2022-09-15T13:00:00-04:00https://pasithea.com/pasithea-therapeutics-to-present-at-the-h-c-wainwright-24th-annual-global-investment-conference/2022-09-09T15:32:00-04:00https://pasithea.com/pasithea-therapeutics-to-present-results-of-tolerizing-vaccine-program-at-prestigious-international-immunotherapy-conference/2022-08-18T13:00:00-04:00https://pasithea.com/pasithea-therapeutics-announces-results-of-preclinical-study-demonstrating-tolerizing-vaccine-efficacy-in-relapsing-remitting-model-of-multiple-sclerosis/2022-08-11T13:00:00-04:00https://pasithea.com/pasithea-therapeutics-urges-stockholders-to-reject-activist-camac-groups-unjustified-campaign/2022-08-02T12:00:00-04:00https://pasithea.com/pasithea-therapeutics-awarded-a-drug-development-research-grant/2022-07-14T13:00:00-04:00https://pasithea.com/pasithea-therapeutics-to-participate-in-the-h-c-wainwright-1st-annual-mental-health-conference-neuropsychiatry-psychedelics-and-beyond/2022-06-23T13:00:00-04:00https://pasithea.com/pasithea-therapeutics-acquires-alpha-5-integrin-llc/2022-06-22T13:00:00-04:00https://pasithea.com/pasithea-therapeutics-to-present-at-the-noblecon18-investor-conference-2022/2022-04-14T21:15:00-04:00https://pasithea.com/pasithea-therapeutics-announces-financial-and-business-results-for-the-fourth-quarter-and-full-year-2021-and-business-update-for-2022/2022-03-30T21:15:00-04:00https://pasithea.com/pasithea-therapeutics-announces-collaboration-with-the-glimpse-group/2022-03-08T14:00:00-05:00https://pasithea.com/pasithea-therapeutics-announces-plans-to-open-three-new-clinics-in-the-uk-by-mid-2022/2022-02-24T14:00:00-05:00https://pasithea.com/pasithea-therapeutics-strengthens-its-scientific-advisory-board-with-the-appointment-of-preeminent-scientist-dr-daniel-weinberger/2022-02-09T14:00:00-05:00https://pasithea.com/pasithea-therapeutics-initiates-new-chemical-entity-drug-development-program-in-multiple-sclerosis/2022-02-03T14:00:00-05:00https://pasithea.com/pasithea-therapeutics-announces-opening-of-mental-health-clinic-in-los-angeles-and-broadens-focus-beyond-ketamine-treatments/2022-01-26T14:00:00-05:00https://pasithea.com/pasithea-therapeutics-opens-second-ketamine-therapy-clinic-in-the-united-kingdom/2021-12-21T14:00:00-05:00https://pasithea.com/pasithea-therapeutics-expands-its-mobile-clinics-into-florida-and-nevada/2021-12-01T14:00:00-05:00https://pasithea.com/pasithea-therapeutics-corp-announces-closing-of-30-4-million-private-placement-priced-at-a-premium-to-the-market-under-nasdaq-rules/2021-11-29T23:45:00-05:00https://pasithea.com/pasithea-therapeutics-corp-announces-pricing-of-a-30-4-million-private-placement-priced-at-a-premium-to-the-market-under-nasdaq-rules/2021-11-24T14:52:00-05:00https://pasithea.com/pasithea-therapeutics-adds-esketamine-nasal-spray-to-its-clinic-offerings-in-the-u-k/2021-11-23T14:00:00-05:00https://pasithea.com/pasithea-therapeutics-launches-in-home-intravenous-ketamine-therapy-in-major-u-s-cities-expanding-its-international-footprint/2021-11-17T14:00:00-05:00https://pasithea.com/pasithea-therapeutics-collaborates-with-renowned-musician-and-producer-to-create-soundtracks-for-ketamine-therapy/2021-11-11T14:00:00-05:00https://pasithea.com/pasithea-therapeutics-corp-establishes-scientific-advisory-board-and-names-dr-charles-b-nemeroff-as-chair/2021-11-09T14:00:00-05:00https://pasithea.com/pasithea-therapeutics-announces-successful-treatment-of-first-patients-in-the-uk-with-ketamine-infusion-therapy/2021-10-27T12:45:00-04:00https://pasithea.com/pasithea-therapeutics-opens-its-first-ketamine-therapy-clinic-in-the-united-kingdom/2021-10-14T12:45:00-04:00https://pasithea.com/pasithea-therapeutics-corp-and-evotec-se-enter-into-drug-development-agreement/2021-10-11T11:50:00-04:00https://pasithea.com/pasithea-therapeutics-corp-to-present-at-the-benzinga-healthcare-small-cap-conference/2021-09-29T21:30:00-04:00https://pasithea.com/pasithea-therapeutics-corp-announces-closing-of-24-0-million-initial-public-offering/2021-09-17T21:05:00-04:00https://pasithea.com/pasithea-therapeutics-corp-announces-pricing-of-upsized-24-0-million-initial-public-offering/2021-09-15T02:04:00-04:00https://pasithea.com/pasithea-therapeutics-announces-orphan-drug-designation-by-fda-of-pas-004-for-treatment-of-amyotrophic-lateral-sclerosis-als/2026-06-02T07:02:06-04:00https://pasithea.com/pasithea-therapeutics-announces-exhibit-at-childrens-tumor-foundation-2026-nf-conference/2026-06-15T07:02:29-04:00https://pasithea.com/pasithea-therapeutics-announces-amendments-to-clinical-study-protocol-for-phase-1-1b-nf1-clinical-trial/2026-06-16T07:00:27-04:00https://pasithea.com/pasithea-therapeutics-announces-positive-interim-phase-1-advanced-cancer-study-data-demonstrating-long-term-safety-and-tolerability-and-durable-clinical-activity-in-mek-braf-pretreated-patients-plus/2026-06-30T07:00:25-04:00https://pasithea.com/pasithea-therapeutics-announces-participation-in-b-riley-securities-mind-muscle-vision-summit/2026-07-08T07:02:26-04:00https://pasithea.com/pasithea-therapeutics-announces-presentation-of-pas-004-data-to-european-society-for-medical-oncology-esmo-congress-2026/2026-07-21T07:00:11-04:00https://pasithea.com/pasithea-therapeutics-announces-participation-in-two-september-2026-investor-conferences/2026-09-03T16:05:36-04:00https://pasithea.com/pasithea-therapeutics-announces-presentation-of-initial-pas-004-clinical-data-from-ongoing-phase-1-1b-clinical-trial-in-adult-nf1-patients-at-the-2026-european-neurofibromatosis-conference/2026-09-14T07:00:23-04:00